Titan Pharmaceuticals — Investor Presentation (February 2016)
22 slides from Titan Pharmaceuticals's investor presentation, Feb 2, 2016
Slide 1: Corporate Presentation
Corporate Presentation Sunil Bhonsle Jan 2016
Slide 2: Forward-Looking Statements
Forward - Looking Statements The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future o
Slide 3: Company Overview
Company Overview Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases utilizing its proprietary ProNeura ™ technology platform • ProNeura: Proprietary Long - term Drug Delivery Platform • Provides continuous drug release and non - fluctuating medication leve
Slide 4: The Epidemic of Opioid Addiction
The Epidemic of Opioid Addiction • Increasingly recognized as a global epidemic by world health authorities • Addiction - a primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry • Cravings, accompanied by lack of impulse control • Abstinence is rarely a successfu
Slide 5: Opioid Addiction: Treatment Overview
Opioid Addiction: Treatment Overview • Buprenorphine pharmacology makes it an effective, safer and more convenient treatment option • Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients • Convenient outpatient treatment allowing take home medication, unlike methado
Slide 6: Proprietary ProNeura Technology: Probuphine Implant
Buprenorphine Probuphine EVA polymer Proprietary ProNeura Technology: Probuphine Implant • Implant contains 80 mg of buprenorphine HCl, uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping 6 Titan Pharmaceuticals Comp
Slide 7: Probuphine Administration
Probuphine Administration 7 Four probuphine implants are inserted subdermally in the inner, upper arm in a brief office procedure. After six months, the implants are removed and new implants may be inserted in the opposite arm.
Slide 8: Probuphine Value Proposition
Probuphine Value Proposition Probuphine is the first and only potential treatment for opioid dependence that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months 8 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Ph
Slide 9: Probuphine Clinical and Regulatory History
• Six clinical studies completed and NDA submitted in October 2012 • NDA accepted for Priority Review in January 2013 • Positive advisory committee vote (10 - 4 for approval) in March 2013 • Receipt of CRL in April 2013 requesting additional clinical testing and a few other items • Additional Phase
Slide 10: Positive Results From PRO-814 Phase 3 Study
Positive Results From PRO 814 Phase 3 Study • Primary efficacy endpoint based on non - inferiority comparison of ‘responders’ following six months of treatment with either four Probuphine implants or 8 mg or less of an approved daily dosed sublingual tablet formulation of buprenorphine 10 Titan Phar
Slide 11: Advisory Committee Meeting (January 2016)
Advisory Committee Meeting (January 2016) • Focus of the discussion: • Efficacy - What is the most appropriate definition of a treatment responder, given the use of supplemental “dose adjustments,” and missing or incomplete urine toxicology data ? • Safety/HF validation - Given the possibility of pr
Slide 12: Probuphine Summary - The First of its Kind
Probuphine Summary - The First of its Kind • NDA review in process with FDA action date of February 27, 2016 • Partnership with Braeburn Pharmaceuticals for development and commercialization in U.S. and Canada • Upfront: $15.75 mil; Approval: $15 mil; Sales Milestones: $165 mil; Tiered Royalties: mi
Slide 13: Titan: Adding Value Beyond Probuphine
Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • Long - term drug delivery technology validated through the Probuphine program • Potential for the treatment of select chronic diseases for which low dose, long - term delivery and stable drug levels may offer advantages
Slide 14: Parkinson's Disease Overview
. Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pharmaceutical, Inc. 14 Definition Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function Treatment Treated with drugs designed to replace or mimic dopa
Slide 15: Parkinson's Disease Population Increasing Worldwide
Parkinson’s Disease Population Increasing Worldwide 15 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material. Titan Pharmaceuticals Company Overview
Slide 16: Parkinson's Disease - Therapeutics Market
Parkinson’s Disease - Therapeutics Market • As many as one million people in the US affected by Parkinson’s disease • The number is expected to almost double by 2030 because of the aging population • About 60,000 newly diagnosed for Parkinson’s disease annually • More than 23,000 die from Parkinson’
Slide 17: ProNeura Parkinson's Disease Program
ProNeura Parkinson’s Disease Program • Ropinirole ( Requip ® ), a generic dopamine agonist marketed by GSK for PD, was evaluated in a Parkinsonian primate model using ProNeura drug delivery platform • Results demonstrated • Sustained plasma ropinirole levels for several months following implantation
Slide 18: Hypothyroidism Overview
. Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pharmaceutical, Inc. 18 Definition Hypothyroidism is a disorder that occurs when the thyroid gland does not make enough thyroid hormone to meet the body’s needs Thyroid hormone regulates metabolism and affects nearly
Slide 19: ProNeura Hypothyroidism Program
ProNeura Hypothyroidism Program • Completed initial formulation development of the implant and conducted in - vitro and in - vivo drug release studies to further define implant formulation • In - vivo non - clinical studies in progress evaluating implant formulations for drug release characteristics
Slide 20: Titan Pharmaceuticals Summary
Titan Pharmaceuticals Summary • Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases, utilizing its innovative ProNeura long term drug delivery platform • Probuphine, a six month buprenorphine implant for the maintenance treatment of opioid addiction; NDA re
Slide 21: Titan Executive Management
• Marc Rubin, M.D, Executive Chairman and Director • 8 years with Titan Pharmaceuticals • Former Head of Global Research & Development and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 25 years in the pharmaceutical industry f
Slide 22: Thank You
Thank You Sunil Bhonsle Jan 2016
Titan Pharmaceuticals — Investor Presentation (February 2016) on 6ix